Alkem Laboratories Ltd., founded in 1973 by Samprada Singh and Basudeo Narain Singh in Mumbai, India, is a leading pharmaceutical powerhouse specializing in the development, manufacturing, and marketing of **branded generics, generic drugs, active pharmaceutical ingredients (APIs), nutraceuticals, and biosimilars** across major therapeutic segments.[1][2][3] From humble beginnings aimed at transforming India's pharma sector, Alkem has evolved over **five decades** into a global player with a footprint in **over 50 countries**, including the US via its subsidiary Ascend, LATAM, Europe, Africa, CIS, Southeast Asia, and Australia.[1][3][4] It operates **19 state-of-the-art manufacturing facilities** (all US FDA-approved in India and the US) and **five cutting-edge R&D centers** in India and the US, employing over 500 scientists to drive innovation under its "Extended Lifecare Beyond Boundaries" philosophy.[1][3] **Key achievements** include consistent ranking among India's **top 10 pharmaceutical companies**, leadership in acute therapies like anti-infectives (held for over a decade), gastro-intestinal, pain management, and vitamins/minerals for more than 10 years, with blockbuster brands such as **Clavam, Pan, Pan-D, and Taxim-O** featuring in India's top 50 pharma brands.[1][3] The company boasts **over 800 brands**, cumulative **125+ ANDA filings** and approvals with the US FDA, and approved drugs like Olanzapine for schizophrenia, Dronabinol for nausea, and Evogliptin for type 2 diabetes, plus pipelines in biosimilars (e.g., Denosumab) and novel therapies.[1][2][4] Its diversified portfolio mitigates risks while fueling growth in both US and non-US markets.[1] Today, Alkem emphasizes **accessibilit